XELJANZ® (tofacitinib) for the Treatment of Moderately to Severely Active Ulcerative Colitis
On May 30th, 2018, the Pfizer corporation, announced that the Food and Drug Administration (FDA) has approved its application to allow for Xeljanz to be used by ulcerative colitis patients who meet certain criteria.
There are some more details listed on the Pfizer website about this new medicinal product of theirs. You can read the full press release here: https://press.pfizer.com/press-release/pfizer-announces-us-fda-approves-xeljanz-tofacitinib-treatment-moderately-severely-act
What would be excellent is for the current and future UC’ers of the world who have experience with Xeljanz (Tofacitinib) to start including their reviews of this on this page, both reviews of how it went, and as well any potential side effects.
Add Your Review Below:
Submit your review